Is Aura Biosciences, Inc. (AURA) a Buy, Sell, or Hold?
Aura Biosciences, Inc.
NASDAQ:AURA
$7 USD
$0 (0.0%)
- Volume
- 630.14K
- Average Volume
- 646.08K
- Market Capitalization
- $449.4M
- P/E Ratio
- -3.95
- Dividend Yield
- 0.00%
- Price Target
- $17.00
- Year High
- $9.54
- Year Low
- $4.73
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.09
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Elisabet de los Pinos |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | AURA |
| CUSIP | 05153U107 |
| CIK | 0001501796 |
| Web | https://www.aurabiosciences.com |
| Phone | 617 500 8864 |
| Currency | USD |
| Employees | 113 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.16 |
| Payout Ratio | 0.00 |
| Current Ratio | 7.09 |
| Quick Ratio | 7.09 |
| Cash Ratio | 5.08 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -1.36 |
| Price / Cash Flow | -4.90 |
| Price / Book | 4.40 |
Price Target and Rating
| Average Stock Price Forecast | $17.00 |
| High Stock Price Forecast | $17.00 |
| Low Stock Price Forecast | $17.00 |
| Forecast Upside/Downside | -58.82% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 8 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.76 |
| Trailing P/E Ratio | -3.95 |
| PEG Ratio | -0.59 |
| P/E Growth | -0.59 |
| Net Income | $-106.19M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -78.12% |
| Return on Assets | -81.64% |
Financials Score
| AltmanZ Score | 1.68 |
| Piotroski Score | 1.00 |
| Working Capital | 101.8M |
| Total Assets | 137.68M |
| Ebit | -112.29M |
| Market Cap | 442.02M |
| Total Liabilities | 30.43M |
Poll Results
About Aura Biosciences, Inc. (NASDAQ:AURA) Stock
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases. ...
Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors
2026-07-08 07:01:00
BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Jeremy Bender, Ph.D., M.B.A., to its Board of Directors.
2026-06-17 07:00:00
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2026) - Auranova Resources Inc. (TSXV: AURA) ("Auranova" or the "Company") and Kenorland Minerals Ltd. ("Kenorland") are pleased to announce complete assay results from the 2026 spring (phase 3) diamond drill program at the South Uchi Project (the "Project"), located in the Red Lake District of Ontario.
2026-06-01 08:00:00
Enrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial Topline data from the 15-month primary endpoint expected in the second half of 2027 BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced it has completed enrollment of 108 patients in the Phase 3 trial evaluating belzupacap sarotalocan (bel-sar) as a frontline treatment for patients with early choroidal melanoma. Topline data for the 15-month primary endpoint are anticipated in the second half of 2027.
Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances
2026-05-27 16:06:31
Aura Biosciences NASDAQ: AURA is shifting its focus toward regulatory preparation and commercialization planning as enrollment in its registrational CoMpass study of bel-sar in early choroidal melanoma nears completion, newly appointed CEO Natalie Holles said during a fireside chat at TD Cowen's seventh annual Oncology Innovation Summit.
Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data
2026-05-19 22:02:46
Aura Biosciences NASDAQ: AURA executives outlined the company's strategy for its lead candidate bel-sar during a session at the H.C. Wainwright Connect Conference, emphasizing ocular oncology as the company's initial development focus while also discussing ongoing work in non-muscle invasive bladder cancer.
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-05-19 16:50:00
BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that inducement equity awards (collectively, “Inducement Awards”) were granted to Natalie Holles, Aura's new Chief Executive Officer and President, on May 19, 2026 (the “Grant Date”). The Inducement Awards are consistent with the previously disclosed terms of Ms. Holles' offer letter and were approved by the Board of Directors of the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Aura Biosciences to Participate in Upcoming Investor Conferences
2026-05-12 16:01:00
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences: H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq on Tuesday, May 19, 2026.
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
2026-05-11 16:01:00
Phase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline data Natalie Holles appointed Chief Executive Officer and President and member of the Board of Directors Strengthened balance sheet with oversubscribed $299 million equity financing; cash position expected to fund operations into 2H 2028 BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights. “We are entering a pivotal period for Aura as we advance our Phase 3 CoMpass trial toward enrollment completion and potential registration,” said Natalie Holles, Chief Executive Officer of Aura Biosciences.
Frequently Asked Questions
-
What is the current Aura Biosciences, Inc. (AURA) stock price?
-
Aura Biosciences, Inc.(NASDAQ:AURA) stock price is $7 in the last trading session. During the trading session, AURA stock reached the peak price of $9.535 while $4.73 was the lowest point it dropped to. The percentage change in AURA stock occurred in the recent session was 0.0% while the dollar amount for the price change in AURA stock was $0.
-
AURA's industry and sector of operation?
-
The NASDAQ listed AURA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of AURA?
-
Anthony Daniels | Vice President & Therapeutic Area of Head Ocular Oncology
Jill Hopkins | Chief Medical Officer & President of Research and Development
Mark Plavsic | Chief Technology Officer
Conor Kilroy | Chief Legal Officer & Secretary
Joe McQuaid | VP & Therapeutic Area Head of Urologic Oncology -
How many employees does AURA have?
-
Number of AURA employees currently stands at 113. AURA operates from 85 Bolton Street, Boston, MA 02140, US.
-
Link for AURA official website?
-
Official Website of AURA is: https://www.aurabiosciences.com
-
How do I contact AURA?
-
AURA could be contacted at phone #617 500 8864 and can also be accessed through its website. AURA operates from 85 Bolton Street, Boston, MA 02140, US.
-
How many shares of AURA are traded daily?
-
The average number of AURA shares traded daily for last 3 months was 646.08K.
-
What is the market cap of AURA currently?
-
The market value of AURA currently stands at $449.4M with its latest stock price at $7